EP300 and pancreatic adenocarcinoma: To explore the prediction values of CTCF, PACERR and EP300 in PDAC, we performed survival analysis based on the median expression status of a multi‐gene signature of CTCF, PACERR and EP300 for PAAD patients in The Cancer Genome Atlas (TCGA) database and plot Kaplan‐Meier curves, revealing that a high expression of the multi‐signature of CTCF, PACERR and EP300 was significantly associated with poor OS (Figure 8D) and disease‐free survival (Figure 8E).